MedTrace Logo

Burst Biologics Spinal Fusion Registry

NCT03064802 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2019-12-30

No results posted yet for this study

Summary

A multicenter patient registry was created with aim of documenting how spine and neurosurgeons are utilizing Burst Biologics products along with patient outcomes. These include radiographic measures such as fusion outcome, instrumentation integrity, and clinical outcomes (symptom and function improvement) based on surgeon and patient based outcome assessments.

Conditions

  • Degenerative Disc Disease
  • Spinal Stenosis
  • Spondylitis
  • Spondylolisthesis
  • Herniated Disk

Interventions

DEVICE

BioBurst Fluid, Burst Allograft

BioBurst Fluid or Burst Allograft used to augment spinal fusion

Sponsors & Collaborators

  • Burst Biologics

    lead INDUSTRY

Principal Investigators

  • Steven M Czop, R.Ph. · Medical Affairs Officer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-24
Primary Completion
2020-06-30
Completion
2020-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03064802 on ClinicalTrials.gov